UK backs Lucentis for new use after Novartis cuts price
LONDON (Reuters) - Britain's healthcare cost watchdog has given its backing to eye drug Lucentis to treat diabetes-related problems after Swiss drugmaker Novartis offered it at a discount to the National Health Service.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
More News: Diabetes | Endocrinology | Health | Lucentis | National Health Service (NHS) | Ranibizumab Injection | UK Health